---
document_datetime: 2025-12-02 05:23:26
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/fulvestrant-mylan.html
document_name: fulvestrant-mylan.html
version: success
processing_time: 0.1349105
conversion_datetime: 2025-12-25 03:21:46.375076
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Fulvestrant Mylan

[RSS](/en/individual-human-medicine.xml/65818)

##### Authorised

This medicine is authorised for use in the European Union

fulvestrant Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Fulvestrant Mylan](#news-on)
- [Product information - with tracked changes](#product-information-with-tracked-changes-80034)
- [More information on Fulvestrant Mylan](#more-information-on-fulvestrant-mylan-1105)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Fulvestrant Mylan. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Fulvestrant Mylan.

For practical information about using Fulvestrant Mylan, patients should read the package leaflet or contact their doctor or pharmacist.

Expand section

Collapse section

## What is Fulvestrant Mylan and what is it used for?

Fulvestrant Mylan is an anti-oestrogen medicine used to treat advanced or metastatic breast cancer (cancer that has spread to other parts of the body) in postmenopausal women with a type of breast cancer known as 'oestrogen-receptor positive cancer' who have not previously had hormonal treatment, or whose cancer had come back after treatment with another anti-oestrogen.

Fulvestrant Mylan contains the active substance fulvestrant.

Fulvestrant Mylan is a 'generic medicine'. This means that Fulvestrant Mylan contains the same active substance and works in the same way as a 'reference medicine' already authorised in the European Union (EU) called Faslodex.

## How is Fulvestrant Mylan used?

Fulvestrant Mylan can only be obtained with a prescription and is available as a solution for injection in prefilled syringes (250 mg). The recommended dose is 500 mg given once a month, with an additional 500-mg dose given two weeks after the first dose. The dose is given as two injections, each given into the muscle of one buttock over one to two minutes.

## How does Fulvestrant Mylan work?

Most types of breast cancer are stimulated to grow when the hormone oestrogen attaches to targets (receptors) on cancer cells. The active substance in Fulvestrant Mylan, fulvestrant, is an anti-oestrogen. It blocks the receptors for oestrogen on cells and causes the number of oestrogen receptors to fall. As a result, the cancer cells are not stimulated to grow by oestrogen and this slows down the growth of the tumour.

## How has Fulvestrant Mylan been studied?

Studies on the benefits and risks of the active substance in the approved use have already been carried out with the reference medicine, Faslodex, and do not need to be repeated for Fulvestrant Mylan.

As for every medicine, the company provided studies on the quality of Fulvestrant Mylan. There was no need for 'bioequivalence' studies to investigate whether Fulvestrant Mylan is absorbed similarly to the reference medicine to produce the same level of the active substance in the blood. This is because the composition of Fulvestrant Mylan is the same as the reference medicine and when given by injection into the muscle, the active substance in both products is expected to be absorbed in the same way.

## What are the benefits and risks of Fulvestrant Mylan?

Because Fulvestrant Mylan is a generic medicine, its benefits and risks are taken as being the same as the reference medicine's.

## Why is Fulvestrant Mylan approved?

The European Medicines Agency concluded that, in accordance with EU requirements, Fulvestrant Mylan has been shown to be comparable to Faslodex. Therefore, the Agency's view was that, as for Faslodex, the benefit outweighs the identified risk. The Agency recommended that Fulvestrant Mylan be approved for use in the EU.

## What measures are being taken to ensure the safe and effective use of Fulvestrant Mylan?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Fulvestrant Mylan have been included in the summary of product characteristics and the package leaflet.

## Other information about Fulvestrant Mylan

The European Commission granted a marketing authorisation valid throughout the European Union for Fulvestrant Mylan on 8 January 2018.

For more information about treatment with Fulvestrant Mylan, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Fulvestrant Mylan : EPAR - Summary for the public

Reference Number: EMA/CHMP/810299/2017

English (EN) (91.63 KB - PDF)

**First published:** 02/02/2018

**Last updated:** 21/02/2018

[View](/en/documents/overview/fulvestrant-mylan-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-551)

български (BG) (109.46 KB - PDF)

**First published:**

02/02/2018

**Last updated:**

21/02/2018

[View](/bg/documents/overview/fulvestrant-mylan-epar-summary-public_bg.pdf)

español (ES) (84.21 KB - PDF)

**First published:**

02/02/2018

**Last updated:**

21/02/2018

[View](/es/documents/overview/fulvestrant-mylan-epar-summary-public_es.pdf)

čeština (CS) (107.87 KB - PDF)

**First published:**

02/02/2018

**Last updated:**

21/02/2018

[View](/cs/documents/overview/fulvestrant-mylan-epar-summary-public_cs.pdf)

dansk (DA) (83.63 KB - PDF)

**First published:**

02/02/2018

**Last updated:**

21/02/2018

[View](/da/documents/overview/fulvestrant-mylan-epar-summary-public_da.pdf)

Deutsch (DE) (84.98 KB - PDF)

**First published:**

02/02/2018

**Last updated:**

21/02/2018

[View](/de/documents/overview/fulvestrant-mylan-epar-summary-public_de.pdf)

eesti keel (ET) (83.02 KB - PDF)

**First published:**

02/02/2018

**Last updated:**

21/02/2018

[View](/et/documents/overview/fulvestrant-mylan-epar-summary-public_et.pdf)

ελληνικά (EL) (112.91 KB - PDF)

**First published:**

02/02/2018

**Last updated:**

21/02/2018

[View](/el/documents/overview/fulvestrant-mylan-epar-summary-public_el.pdf)

français (FR) (84.6 KB - PDF)

**First published:**

02/02/2018

**Last updated:**

21/02/2018

[View](/fr/documents/overview/fulvestrant-mylan-epar-summary-public_fr.pdf)

hrvatski (HR) (102.51 KB - PDF)

**First published:**

02/02/2018

**Last updated:**

21/02/2018

[View](/hr/documents/overview/fulvestrant-mylan-epar-summary-public_hr.pdf)

italiano (IT) (83.34 KB - PDF)

**First published:**

02/02/2018

**Last updated:**

21/02/2018

[View](/it/documents/overview/fulvestrant-mylan-epar-summary-public_it.pdf)

latviešu valoda (LV) (104.17 KB - PDF)

**First published:**

02/02/2018

**Last updated:**

21/02/2018

[View](/lv/documents/overview/fulvestrant-mylan-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (105.38 KB - PDF)

**First published:**

02/02/2018

**Last updated:**

21/02/2018

[View](/lt/documents/overview/fulvestrant-mylan-epar-summary-public_lt.pdf)

magyar (HU) (102.1 KB - PDF)

**First published:**

02/02/2018

**Last updated:**

21/02/2018

[View](/hu/documents/overview/fulvestrant-mylan-epar-summary-public_hu.pdf)

Malti (MT) (107.9 KB - PDF)

**First published:**

02/02/2018

**Last updated:**

21/02/2018

[View](/mt/documents/overview/fulvestrant-mylan-epar-summary-public_mt.pdf)

Nederlands (NL) (84.11 KB - PDF)

**First published:**

02/02/2018

**Last updated:**

21/02/2018

[View](/nl/documents/overview/fulvestrant-mylan-epar-summary-public_nl.pdf)

polski (PL) (108.48 KB - PDF)

**First published:**

02/02/2018

**Last updated:**

21/02/2018

[View](/pl/documents/overview/fulvestrant-mylan-epar-summary-public_pl.pdf)

português (PT) (84.01 KB - PDF)

**First published:**

02/02/2018

**Last updated:**

21/02/2018

[View](/pt/documents/overview/fulvestrant-mylan-epar-summary-public_pt.pdf)

română (RO) (104.56 KB - PDF)

**First published:**

02/02/2018

**Last updated:**

21/02/2018

[View](/ro/documents/overview/fulvestrant-mylan-epar-summary-public_ro.pdf)

slovenčina (SK) (107.8 KB - PDF)

**First published:**

02/02/2018

**Last updated:**

21/02/2018

[View](/sk/documents/overview/fulvestrant-mylan-epar-summary-public_sk.pdf)

slovenščina (SL) (101.64 KB - PDF)

**First published:**

02/02/2018

**Last updated:**

21/02/2018

[View](/sl/documents/overview/fulvestrant-mylan-epar-summary-public_sl.pdf)

Suomi (FI) (83.57 KB - PDF)

**First published:**

02/02/2018

**Last updated:**

21/02/2018

[View](/fi/documents/overview/fulvestrant-mylan-epar-summary-public_fi.pdf)

svenska (SV) (83.85 KB - PDF)

**First published:**

02/02/2018

**Last updated:**

21/02/2018

[View](/sv/documents/overview/fulvestrant-mylan-epar-summary-public_sv.pdf)

## Product information

Fulvestrant Mylan : EPAR - Product Information

English (EN) (494.22 KB - PDF)

**First published:** 02/02/2018

**Last updated:** 09/10/2025

[View](/en/documents/product-information/fulvestrant-mylan-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-578)

български (BG) (729.92 KB - PDF)

**First published:**

02/02/2018

**Last updated:**

09/10/2025

[View](/bg/documents/product-information/fulvestrant-mylan-epar-product-information_bg.pdf)

español (ES) (422.48 KB - PDF)

**First published:**

02/02/2018

**Last updated:**

09/10/2025

[View](/es/documents/product-information/fulvestrant-mylan-epar-product-information_es.pdf)

čeština (CS) (448.23 KB - PDF)

**First published:**

02/02/2018

**Last updated:**

09/10/2025

[View](/cs/documents/product-information/fulvestrant-mylan-epar-product-information_cs.pdf)

dansk (DA) (542.49 KB - PDF)

**First published:**

02/02/2018

**Last updated:**

09/10/2025

[View](/da/documents/product-information/fulvestrant-mylan-epar-product-information_da.pdf)

Deutsch (DE) (703.66 KB - PDF)

**First published:**

02/02/2018

**Last updated:**

09/10/2025

[View](/de/documents/product-information/fulvestrant-mylan-epar-product-information_de.pdf)

eesti keel (ET) (394.29 KB - PDF)

**First published:**

02/02/2018

**Last updated:**

09/10/2025

[View](/et/documents/product-information/fulvestrant-mylan-epar-product-information_et.pdf)

ελληνικά (EL) (392.31 KB - PDF)

**First published:**

02/02/2018

**Last updated:**

09/10/2025

[View](/el/documents/product-information/fulvestrant-mylan-epar-product-information_el.pdf)

français (FR) (365.94 KB - PDF)

**First published:**

02/02/2018

**Last updated:**

09/10/2025

[View](/fr/documents/product-information/fulvestrant-mylan-epar-product-information_fr.pdf)

hrvatski (HR) (1.15 MB - PDF)

**First published:**

02/02/2018

**Last updated:**

09/10/2025

[View](/hr/documents/product-information/fulvestrant-mylan-epar-product-information_hr.pdf)

íslenska (IS) (471.6 KB - PDF)

**First published:**

02/02/2018

**Last updated:**

09/10/2025

[View](/is/documents/product-information/fulvestrant-mylan-epar-product-information_is.pdf)

italiano (IT) (303.87 KB - PDF)

**First published:**

02/02/2018

**Last updated:**

09/10/2025

[View](/it/documents/product-information/fulvestrant-mylan-epar-product-information_it.pdf)

latviešu valoda (LV) (566.42 KB - PDF)

**First published:**

02/02/2018

**Last updated:**

09/10/2025

[View](/lv/documents/product-information/fulvestrant-mylan-epar-product-information_lv.pdf)

lietuvių kalba (LT) (592.1 KB - PDF)

**First published:**

02/02/2018

**Last updated:**

09/10/2025

[View](/lt/documents/product-information/fulvestrant-mylan-epar-product-information_lt.pdf)

magyar (HU) (671.71 KB - PDF)

**First published:**

02/02/2018

**Last updated:**

09/10/2025

[View](/hu/documents/product-information/fulvestrant-mylan-epar-product-information_hu.pdf)

Malti (MT) (912.15 KB - PDF)

**First published:**

02/02/2018

**Last updated:**

09/10/2025

[View](/mt/documents/product-information/fulvestrant-mylan-epar-product-information_mt.pdf)

Nederlands (NL) (712.8 KB - PDF)

**First published:**

02/02/2018

**Last updated:**

09/10/2025

[View](/nl/documents/product-information/fulvestrant-mylan-epar-product-information_nl.pdf)

norsk (NO) (505.53 KB - PDF)

**First published:**

02/02/2018

**Last updated:**

09/10/2025

[View](/no/documents/product-information/fulvestrant-mylan-epar-product-information_no.pdf)

polski (PL) (573.7 KB - PDF)

**First published:**

02/02/2018

**Last updated:**

09/10/2025

[View](/pl/documents/product-information/fulvestrant-mylan-epar-product-information_pl.pdf)

português (PT) (399.13 KB - PDF)

**First published:**

02/02/2018

**Last updated:**

09/10/2025

[View](/pt/documents/product-information/fulvestrant-mylan-epar-product-information_pt.pdf)

română (RO) (551.94 KB - PDF)

**First published:**

02/02/2018

**Last updated:**

09/10/2025

[View](/ro/documents/product-information/fulvestrant-mylan-epar-product-information_ro.pdf)

slovenčina (SK) (824.64 KB - PDF)

**First published:**

02/02/2018

**Last updated:**

09/10/2025

[View](/sk/documents/product-information/fulvestrant-mylan-epar-product-information_sk.pdf)

slovenščina (SL) (442.03 KB - PDF)

**First published:**

02/02/2018

**Last updated:**

09/10/2025

[View](/sl/documents/product-information/fulvestrant-mylan-epar-product-information_sl.pdf)

Suomi (FI) (387.89 KB - PDF)

**First published:**

02/02/2018

**Last updated:**

09/10/2025

[View](/fi/documents/product-information/fulvestrant-mylan-epar-product-information_fi.pdf)

svenska (SV) (739.59 KB - PDF)

**First published:**

02/02/2018

**Last updated:**

09/10/2025

[View](/sv/documents/product-information/fulvestrant-mylan-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** N/0000303636 09/10/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Fulvestrant Mylan : EPAR - All Authorised presentations

English (EN) (44.53 KB - PDF)

**First published:** 02/02/2018

**Last updated:** 24/02/2023

[View](/en/documents/all-authorised-presentations/fulvestrant-mylan-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-514)

български (BG) (72.79 KB - PDF)

**First published:**

02/02/2018

**Last updated:**

24/02/2023

[View](/bg/documents/all-authorised-presentations/fulvestrant-mylan-epar-all-authorised-presentations_bg.pdf)

español (ES) (43.97 KB - PDF)

**First published:**

02/02/2018

**Last updated:**

24/02/2023

[View](/es/documents/all-authorised-presentations/fulvestrant-mylan-epar-all-authorised-presentations_es.pdf)

čeština (CS) (48 KB - PDF)

**First published:**

02/02/2018

**Last updated:**

24/02/2023

[View](/cs/documents/all-authorised-presentations/fulvestrant-mylan-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (64.56 KB - PDF)

**First published:**

02/02/2018

**Last updated:**

24/02/2023

[View](/da/documents/all-authorised-presentations/fulvestrant-mylan-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (65.33 KB - PDF)

**First published:**

02/02/2018

**Last updated:**

24/02/2023

[View](/de/documents/all-authorised-presentations/fulvestrant-mylan-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (149.78 KB - PDF)

**First published:**

02/02/2018

**Last updated:**

24/02/2023

[View](/et/documents/all-authorised-presentations/fulvestrant-mylan-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (42.09 KB - PDF)

**First published:**

02/02/2018

**Last updated:**

24/02/2023

[View](/el/documents/all-authorised-presentations/fulvestrant-mylan-epar-all-authorised-presentations_el.pdf)

français (FR) (45.49 KB - PDF)

**First published:**

02/02/2018

**Last updated:**

24/02/2023

[View](/fr/documents/all-authorised-presentations/fulvestrant-mylan-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (71.69 KB - PDF)

**First published:**

02/02/2018

**Last updated:**

24/02/2023

[View](/hr/documents/all-authorised-presentations/fulvestrant-mylan-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (42.04 KB - PDF)

**First published:**

02/02/2018

**Last updated:**

24/02/2023

[View](/is/documents/all-authorised-presentations/fulvestrant-mylan-epar-all-authorised-presentations_is.pdf)

italiano (IT) (62.01 KB - PDF)

**First published:**

02/02/2018

**Last updated:**

24/02/2023

[View](/it/documents/all-authorised-presentations/fulvestrant-mylan-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (154.26 KB - PDF)

**First published:**

02/02/2018

**Last updated:**

24/02/2023

[View](/lv/documents/all-authorised-presentations/fulvestrant-mylan-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (154.07 KB - PDF)

**First published:**

02/02/2018

**Last updated:**

24/02/2023

[View](/lt/documents/all-authorised-presentations/fulvestrant-mylan-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (62.41 KB - PDF)

**First published:**

02/02/2018

**Last updated:**

24/02/2023

[View](/hu/documents/all-authorised-presentations/fulvestrant-mylan-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (35.61 KB - PDF)

**First published:**

02/02/2018

**Last updated:**

24/02/2023

[View](/mt/documents/all-authorised-presentations/fulvestrant-mylan-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (43.24 KB - PDF)

**First published:**

02/02/2018

**Last updated:**

24/02/2023

[View](/nl/documents/all-authorised-presentations/fulvestrant-mylan-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (158.03 KB - PDF)

**First published:**

02/02/2018

**Last updated:**

24/02/2023

[View](/no/documents/all-authorised-presentations/fulvestrant-mylan-epar-all-authorised-presentations_no.pdf)

polski (PL) (40.99 KB - PDF)

**First published:**

02/02/2018

**Last updated:**

24/02/2023

[View](/pl/documents/all-authorised-presentations/fulvestrant-mylan-epar-all-authorised-presentations_pl.pdf)

português (PT) (21.43 KB - PDF)

**First published:**

02/02/2018

**Last updated:**

24/02/2023

[View](/pt/documents/all-authorised-presentations/fulvestrant-mylan-epar-all-authorised-presentations_pt.pdf)

română (RO) (45.71 KB - PDF)

**First published:**

02/02/2018

**Last updated:**

24/02/2023

[View](/ro/documents/all-authorised-presentations/fulvestrant-mylan-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (79.62 KB - PDF)

**First published:**

02/02/2018

**Last updated:**

24/02/2023

[View](/sk/documents/all-authorised-presentations/fulvestrant-mylan-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (45.11 KB - PDF)

**First published:**

02/02/2018

**Last updated:**

24/02/2023

[View](/sl/documents/all-authorised-presentations/fulvestrant-mylan-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (44.29 KB - PDF)

**First published:**

02/02/2018

**Last updated:**

24/02/2023

[View](/fi/documents/all-authorised-presentations/fulvestrant-mylan-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (48.86 KB - PDF)

**First published:**

02/02/2018

**Last updated:**

24/02/2023

[View](/sv/documents/all-authorised-presentations/fulvestrant-mylan-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Fulvestrant Mylan Active substance fulvestrant International non-proprietary name (INN) or common name fulvestrant Therapeutic area (MeSH) Breast Neoplasms Anatomical therapeutic chemical (ATC) code L02BA03

### Pharmacotherapeutic group

Endocrine therapy

### Therapeutic indication

Fulvestrant is indicated for the treatment of estrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women:

- not previously treated with endocrine therapy, or
- with disease relapse on or after adjuvant anti-estrogen therapy, or disease progression on antiestrogen therapy.

## Authorisation details

EMA product number EMEA/H/C/004649

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Mylan Pharmaceuticals Limited

Damastown Industrial Park,

Opinion adopted 09/11/2007 Marketing authorisation issued 08/01/2018 Revision 7

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Fulvestrant Mylan : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (200.67 KB - PDF)

**First published:** 22/05/2024

**Last updated:** 09/10/2025

[View](/en/documents/procedural-steps-after/fulvestrant-mylan-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Fulvestrant Mylan : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (120.54 KB - PDF)

**First published:** 15/04/2019

**Last updated:** 22/05/2024

[View](/en/documents/procedural-steps-after/fulvestrant-mylan-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

## Initial marketing authorisation documents

Fulvestrant Mylan : EPAR - Public assessment report

Reference Number: EMA/CHMP/810299/2017

English (EN) (261.21 KB - PDF)

**First published:** 02/02/2018

**Last updated:** 02/02/2018

[View](/en/documents/assessment-report/fulvestrant-mylan-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Fulvestrant Mylan

Adopted

Reference Number: EMA/CHMP/734315/2017

English (EN) (73.46 KB - PDF)

**First published:** 10/11/2017

**Last updated:** 10/11/2017

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-fulvestrant-mylan_en.pdf)

#### News on Fulvestrant Mylan

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 6-9 November 2017](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-6-9-november-2017) 10/11/2017

#### Product information - with tracked changes

The approved product information for this medicine is available below showing the changes since the previous procedure affecting the product information. The same document without tracked changes is above under 'Product information'.

Fulvestrant Mylan : EPAR - Product information - tracked changes

English (EN) (428.5 KB - DOCX)

**First published:** 09/10/2025

[View](/en/documents/product-information-tracked-changes/fulvestrant-mylan-epar-product-information-tracked-changes_en.docx)

[Other languages (24)](#file-language-dropdown-644)

български (BG) (577.11 KB - DOCX)

**First published:**

09/10/2025

[View](/bg/documents/product-information-tracked-changes/fulvestrant-mylan-epar-product-information-tracked-changes_bg.docx)

español (ES) (575.29 KB - DOCX)

**First published:**

09/10/2025

[View](/es/documents/product-information-tracked-changes/fulvestrant-mylan-epar-product-information-tracked-changes_es.docx)

čeština (CS) (1.36 MB - DOC)

**First published:**

09/10/2025

[View](/cs/documents/product-information-tracked-changes/fulvestrant-mylan-epar-product-information-tracked-changes_cs.doc)

dansk (DA) (2.17 MB - DOC)

**First published:**

09/10/2025

[View](/da/documents/product-information-tracked-changes/fulvestrant-mylan-epar-product-information-tracked-changes_da.doc)

Deutsch (DE) (481.16 KB - DOCX)

**First published:**

09/10/2025

[View](/de/documents/product-information-tracked-changes/fulvestrant-mylan-epar-product-information-tracked-changes_de.docx)

eesti keel (ET) (2.09 MB - DOC)

**First published:**

09/10/2025

[View](/et/documents/product-information-tracked-changes/fulvestrant-mylan-epar-product-information-tracked-changes_et.doc)

ελληνικά (EL) (207.74 KB - DOCX)

**First published:**

09/10/2025

[View](/el/documents/product-information-tracked-changes/fulvestrant-mylan-epar-product-information-tracked-changes_el.docx)

français (FR) (450.98 KB - DOCX)

**First published:**

09/10/2025

[View](/fr/documents/product-information-tracked-changes/fulvestrant-mylan-epar-product-information-tracked-changes_fr.docx)

hrvatski (HR) (2.22 MB - DOC)

**First published:**

09/10/2025

[View](/hr/documents/product-information-tracked-changes/fulvestrant-mylan-epar-product-information-tracked-changes_hr.doc)

íslenska (IS) (1.61 MB - DOC)

**First published:**

09/10/2025

[View](/is/documents/product-information-tracked-changes/fulvestrant-mylan-epar-product-information-tracked-changes_is.doc)

italiano (IT) (1.44 MB - DOC)

**First published:**

09/10/2025

[View](/it/documents/product-information-tracked-changes/fulvestrant-mylan-epar-product-information-tracked-changes_it.doc)

latviešu valoda (LV) (477.2 KB - DOCX)

**First published:**

09/10/2025

[View](/lv/documents/product-information-tracked-changes/fulvestrant-mylan-epar-product-information-tracked-changes_lv.docx)

lietuvių kalba (LT) (1.71 MB - DOC)

**First published:**

09/10/2025

[View](/lt/documents/product-information-tracked-changes/fulvestrant-mylan-epar-product-information-tracked-changes_lt.doc)

magyar (HU) (627.9 KB - DOCX)

**First published:**

09/10/2025

[View](/hu/documents/product-information-tracked-changes/fulvestrant-mylan-epar-product-information-tracked-changes_hu.docx)

Malti (MT) (727.47 KB - DOCX)

**First published:**

09/10/2025

[View](/mt/documents/product-information-tracked-changes/fulvestrant-mylan-epar-product-information-tracked-changes_mt.docx)

Nederlands (NL) (1.5 MB - DOC)

**First published:**

09/10/2025

[View](/nl/documents/product-information-tracked-changes/fulvestrant-mylan-epar-product-information-tracked-changes_nl.doc)

norsk (NO) (581 KB - DOC)

**First published:**

09/10/2025

[View](/no/documents/product-information-tracked-changes/fulvestrant-mylan-epar-product-information-tracked-changes_no.doc)

polski (PL) (1.46 MB - DOC)

**First published:**

09/10/2025

[View](/pl/documents/product-information-tracked-changes/fulvestrant-mylan-epar-product-information-tracked-changes_pl.doc)

português (PT) (331.05 KB - DOCX)

**First published:**

09/10/2025

[View](/pt/documents/product-information-tracked-changes/fulvestrant-mylan-epar-product-information-tracked-changes_pt.docx)

română (RO) (514.04 KB - DOCX)

**First published:**

09/10/2025

[View](/ro/documents/product-information-tracked-changes/fulvestrant-mylan-epar-product-information-tracked-changes_ro.docx)

slovenčina (SK) (1.57 MB - DOC)

**First published:**

09/10/2025

[View](/sk/documents/product-information-tracked-changes/fulvestrant-mylan-epar-product-information-tracked-changes_sk.doc)

slovenščina (SL) (1.42 MB - DOC)

**First published:**

09/10/2025

[View](/sl/documents/product-information-tracked-changes/fulvestrant-mylan-epar-product-information-tracked-changes_sl.doc)

Suomi (FI) (2.33 MB - DOC)

**First published:**

09/10/2025

[View](/fi/documents/product-information-tracked-changes/fulvestrant-mylan-epar-product-information-tracked-changes_fi.doc)

svenska (SV) (444.07 KB - DOCX)

**First published:**

09/10/2025

[View](/sv/documents/product-information-tracked-changes/fulvestrant-mylan-epar-product-information-tracked-changes_sv.docx)

#### More information on Fulvestrant Mylan

Questions and answers on generic medicines

Reference Number: EMA/393905/2006 Rev. 2

English (EN) (66.45 KB - PDF)

**First published:** 09/07/2007

**Last updated:** 07/12/2012

[View](/en/documents/other/questions-and-answers-generic-medicines_en.pdf)

[Other languages (22)](#file-language-dropdown-211)

български (BG) (93.16 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/bg/documents/other/questions-and-answers-generic-medicines_bg.pdf)

español (ES) (68.3 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/es/documents/other/questions-and-answers-generic-medicines_es.pdf)

čeština (CS) (87.71 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/cs/documents/other/questions-and-answers-generic-medicines_cs.pdf)

dansk (DA) (66.79 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/da/documents/other/questions-and-answers-generic-medicines_da.pdf)

Deutsch (DE) (67.55 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/de/documents/other/questions-and-answers-generic-medicines_de.pdf)

eesti keel (ET) (65.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/et/documents/other/questions-and-answers-generic-medicines_et.pdf)

ελληνικά (EL) (91.29 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/el/documents/other/questions-and-answers-generic-medicines_el.pdf)

français (FR) (68.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fr/documents/other/questions-and-answers-generic-medicines_fr.pdf)

hrvatski (HR) (87.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hr/documents/other/questions-and-answers-generic-medicines_hr.pdf)

italiano (IT) (67.62 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/it/documents/other/questions-and-answers-generic-medicines_it.pdf)

latviešu valoda (LV) (111.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lv/documents/other/questions-and-answers-generic-medicines_lv.pdf)

lietuvių kalba (LT) (86.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lt/documents/other/questions-and-answers-generic-medicines_lt.pdf)

magyar (HU) (85.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hu/documents/other/questions-and-answers-generic-medicines_hu.pdf)

Malti (MT) (89.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/mt/documents/other/questions-and-answers-generic-medicines_mt.pdf)

Nederlands (NL) (66.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/nl/documents/other/questions-and-answers-generic-medicines_nl.pdf)

polski (PL) (88.51 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pl/documents/other/questions-and-answers-generic-medicines_pl.pdf)

português (PT) (68.32 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pt/documents/other/questions-and-answers-generic-medicines_pt.pdf)

română (RO) (86.9 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/ro/documents/other/questions-and-answers-generic-medicines_ro.pdf)

slovenčina (SK) (87.73 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sk/documents/other/questions-and-answers-generic-medicines_sk.pdf)

slovenščina (SL) (84.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sl/documents/other/questions-and-answers-generic-medicines_sl.pdf)

Suomi (FI) (66.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fi/documents/other/questions-and-answers-generic-medicines_fi.pdf)

svenska (SV) (67.11 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sv/documents/other/questions-and-answers-generic-medicines_sv.pdf)

#### Topics

- [Generic and hybrid medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A54)
- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 09/10/2025

## Share this page

[Back to top](#main-content)